Amelioration of vitrectomy-induced cataracts

• US 20060292190A1
• Filed: 05/22/2006
• Published: 12/28/2006
• Est. Priority Date: 05/19/2003
• Status: Active Grant

• Current Assignee: Colby Pharmaceutical Company
• Original Assignee: Othera Pharmaceuticals, Inc. (Colby Pharmaceutical Company)
• Inventors: Matier, William L., Patil, Ghanshyam
• Granted Patent: US 7,589,107 B2
• Time in Patent Office: Days
• US Class Current: 424/400
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears

Abstract

Methods to prevent, inhibit, or slow the development of vitrectomy-induced cataracts are disclosed. The methods comprise administering to the eye of a subject a composition comprising an ophthalmologically acceptable carrier or diluent and at least one hydroxylamine compound in a therapeutically sufficient amount to prevent, inhibit, or slow the development of a vitrectomy-induced cataract in the subject to which the composition is administered.

Claims

1. A method for inhibiting the development of a vitrectomy-induced cataract, comprising administering to the vitreous of a subject undergoing a vitrectomy a composition comprising an ophthalmologically acceptable carrier or diluent and at least one hydroxylamine compound in a therapeutically sufficient amount to inhibit the development of a vitrectomy-induced cataract in the subject.

2. The method of claim 1, wherein the composition is administered before, during or after the vitrectomy is performed.

3. The method of claim 1 wherein the composition is administered to achieve in the vitreous tissue and fluids of the subject a concentration of about 0.1 μ

M to about 10 mM.

4. The method of claim 1 wherein the composition is administered to achieve in the vitreous tissue and fluids of the subject a concentration of about 1 μ

M to about 5 mM.

5. The method of claim 1 wherein the composition is administered to achieve in the vitreous tissue and fluids of the subject a concentration of about 10 μ

M to about 2.5 mM.

6. The method of claim 1 wherein the composition is administered to achieve in the vitreous tissue and fluids of the subject a concentration of about 50 μ

M to about 1 mM.

7. The method of claim 1 wherein the composition is administered to achieve in the eye tissue and fluids of the subject a concentration of about 1 μ

M to about 100 μ

M.

8. The method of claim 1 wherein the hydroxylamine compound is at least one of tempol-H, tempo-H, oxano-H, or a compound having the formula:

9. The method of claim 8 wherein the hydroxylamine compound is 1-hydroxy-4-cyclopropanecarbonyloxy-2,2,6,6-tetramethylpiperidine hydrochloride.

10. The method of claim 1 further comprising administering a reducing agent to the vitreous of the subject.

11. The method of claim 10, wherein the reducing agent is coadministered with the composition.

12. The method of claim 10, wherein the reducing agent is formulated as part of the composition.

13. The method of claim 10, wherein the reducing agent is administered separately from the composition.

14. The method of claim 10, wherein the reducing agent is a sulfhydryl compound.

15. The method of claim 14, wherein the reducing agent is mercaptopropionyl glycine, N-acetyl cysteine, β

-mercaptoethylamine or glutathione.

16. The method of claim 1, wherein the composition is administered by injection.

17. The method of claim 1, wherein the composition is coadministered with irrigation solution during vitrectomy.

18. The method of claim 1, wherein the composition is formulated as part of the irrigation solution during vitrectomy.

19. The method of claim 1 further comprising administering to the vitreous of the subject after said vitrectomy a composition comprising an ophthalmologically acceptable carrier or diluent and at least one hydroxylamine compound in a therapeutically sufficient amount to inhibit the development of a vitrectomy-induced cataract in the subject.

20. The method of claim 19, wherein the composition administered after the vitrectomy is performed to achieve in the vitreous tissue and fluids of the subject a hydroxylamine concentration of about 0.1 μ

M to about 10 mM.

21. The method of claim 19, wherein the composition administered after the vitrectomy is injected into the vitreous.

22. The method of claim 19, wherein said composition administered after said vitrectomy is an eyewash, eye drop or ophthalmic ointment.

23. The method of claim 19, wherein the composition administered after said vitrectomy is administered from a polymeric disc or wafer placed on the surface of the eye.

24. The method of claim 19, wherein the hydroxylamine compound is tempol-H, tempo-H, oxano-H, or a compound having the formula:

25. The method of claim 24 wherein a hydroxylamine compound is 1-hydroxy-4-cyclopropanecarbonyloxy-2,2,6,6-tetramethylpiperidine hydrochloride.